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Abstract: 
Background: Biochemical diagnosis of adrenal insufficiency (AI) is difficult in the context of 
traumatic brain injury (TBI).    
Aim: to assess the frequency and predictive factors of AI in victims of TBI from Algiers.   
Methods: Between November 2009 and December 2013, TBI victims had a single 8-9 a.m. 
serum cortisol measurement during the acute post injury period (0-7 days). AI was defined 
according to basal cortisol levels of 83, 276 and 414 nmol/L. Variables studied were TBI 
severity according to Glasgow coma scale, duration of intubation and coma, pupillary status, 
hypotension, anemia, brain imaging findings, diabetes insipidus and medication. Insulin 
tolerance test was performed during the recovery phase, defining AI as peak cortisol <500 
nmol/L. 
 Results:  Cortisol samples were obtained at median 3 (1-7) days from 277 patients (257M: 
20F) aged 32 (18-65) years. Acute AI frequency was 8 (2.8%), 20 (21%) and 35 (37%) 
respectively using the three cortisol cut-offs. Factors predicting AI were diastolic 
hypotension, sedative medication, diabetes insipidus, skull base fracture and intra-
parenchymal haematoma. Mortality was highest in patients with acute cortisol <276nmol/L 
(44.6% with OR for death 1.64, 95% CI 0.92-3.0, p=0.12). During the recovery phase, AI was 
present in 3/3, 12/24, 4/16 and 20/66 patients with week 1 cortisol <83, 83-276, 277-414 and 
>414nmol/L. 
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Conclusion: Hydrocortisone replacement is advised in TBI patients with morning cortisol 
<276 nmol/L or those <414 nmol/L with additional risk factors for AI.  Since acute and 
subsequent AI are poorly correlated patients with moderate/severe TBI require adrenal re-
evaluation during the recovery phase.  
 
Keywords: Traumatic brain injury, adrenal insufficiency, cortisol, skull base fracture, 
diabetes insipidus , diastolic hypopressure, sedative drugs.   
 
Introduction 
Traumatic brain injury (TBI) is a major public health problem and the leading cause of 
disability among young adults [1]. The incidence of TBI in USA is 200 cases /year/100,000 
head of population with 10% requiring hospitalization and 1 in 3 of these patients being 
admitted to intensive care units [2].  A literature review of 23 reports from Europe showed the 
overall incidence (range) of hospitalization for TBI to be 235(150-300)/100,000/year [3].  
Few data are available for the African continent. In West Africa, road traffic accidents (RTA) 
are responsible for 80% of all head traumas in Nigeria alone, while more than half of deaths 
attributed to head injuries from RTA in Africa occur before patients can be admitted to 
hospital [1]. In Guinea, a study of   2829 victims of RTA during the year 2009 showed TBI to 
be present in 82% of cases with median age 27.1 years [4]. In East Africa, a study from 
Uganda showed TBI to be the second reason for admission to an intensive care unit, with 
1774 patients admitted over 7 years [5].  
In the Maghreb countries of North Africa, TBI accounted for 14.4% of admissions in Tunisia, 
particularly in young adults, with a mortality rate of 29% [6]. 
The hypothalamic-pituitary adrenal axis is activated in response to the critical illness caused 
by TBI so that initially cortisol levels are increased. However, adrenocorticotrophic hormone 
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(ACTH) deficiency can be caused by damage, necrosis and hemorrhage in the hypothalamus 
and pituitary [7]. Medications used for the management of the victims in the acute phase of 
brain injury can also induce modifications of cortisol metabolism.  Moreover, critical illness 
may cause a resistance in cortisol action in different tissues caused by cytokine secretion [7-
9]. 
The biochemical diagnosis of adrenal insufficiency (AI) is difficult in the context of critical 
illness such as TBI [10]. In particular, the cut-off for basal cortisol values which constitute AI 
remain controversial. In practice, it is neither feasible nor appropriate to carry out stimulation 
testing such as insulin tolerance test (ITT) to evaluate the corticotrope axis in critically ill 
patients with TBI while the corticotropin stimulation test using 250µg may overestimate 
CTH function [9]. Moreover, the cut-off for this test is not well established in critical illness 
[7-8]. 
It is nevertheless still important to evaluate basal cortisol in TBI despite the lack of 
consensual cut-offs. There is also a need to determine the predictive factors of AI in TBI since 
hydrocortisone treatment of truly deficient patients could improve their outcome.  The aims of 
this study, therefore, were to determine the prevalence of AI in the acute phase of TBI 
according to defined serum cortisol cut-off in an unselected population; to determine what 
factors predicted low cortisol levels; and hence to develop an algorithm for clinical 
management.  A further aim was to re-evaluate adrenal status during the recovery phase of 
TBI and hence determine the relationship between acute and subsequent AI.  
Methods: 
All patients with moderate to severe TBI aged 18-65 years admitted to the Salim Zemirli and 
Central Army hospitals, two neighboring hospitals in the East of Algiers, between November 
2009 and December 2013, were prospectively studied.  Exclusion criteria were the presence 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
of pre-existing endocrine disease including adrenal or pituitary insufficiency, drug or alcohol 
abuse, glucocorticoid intake, and chronic illness.  
The clinical are of patients enrolled into the study was at the discretion of the attending 
critical care physicians, and included the prescription of glucocorticoid in selected subjects. 
Dexamethasone was not given to the patients, in keeping with the evidence to show no benefit  
and increased mortality in TBI patients in whom steroids were given for intra-cerebral lesions 
[10]. 
During the acute post injury period (0-7 days), measurement of serum cortisol was performed  
in all patients between 8 and 9 a.m. on at least one occasion. Cortisol was assayed using the  
Cis-bio RIA. Co-efficients of variation (CVs) for intra-assay precision for 20 points were 
5.5%, 3.6% and 3.7% for mean cortisol values of 64, 251 and 686 nmol/l. CVs for inter-assay 
precision of 10 doublets 5.7%, 8.1% and 6.7% for mean cortisol values of 63, 222 and 565 
nmol/l.                   
Adrenal insufficiency was defined using three cortisol cut-offs: 
 83nmol/l; a value accepted as indicating severe adrenal deficiency [11]. 
 276 nmol/l; a value indicating adrenal deficiency in critical illness according to the 
consensus statements from an international task force by the American College of 
Critical Care Medicine [12]. 
 414nmol/l; a value defined by Cohan et and recommended by Hannon et al as 
indicating AI in victims of TBI [13,14]. 
The variables which were studied as potential associations with AI included: age, severity of 
brain injury; duration of intubation and coma; pupillary status as anisocoria, mydriasis, 
isocoria; and ischaemic factors in terms of arterial hypotension (systolic and/or diastolic blood 
pressure < 90 and 60 mmHg) and anemia (Hb <9dg/ml). The severity of TBI was evaluated 
by GCS [15], graded as severe when GCS was <8, moderate with GCS 8-13.  Computerised 
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tomography (CT) findings were recorded from the first scan within the first 24 hours; the 
presence of skull base fracture was noted. Diabetes insipidus was diagnosed in the context of 
polyuria, hypernatremia >150mmol/l and osmolality>300 mosmol/ Kg in the absence of 
osmotic substance administration. The type of medications used for sedation in intubated 
patients was recorded and comprised: Midazolam (Hypnovel), 2-6-Diisopropilphenol 
(Propofol), Sodium Thiopental  (Penthotal), Fentanyl (Fentanyl) or Sufentanyl (Sufenta) and 
Phenobarbital (Gardenal). 
  Outcome of TBI was evaluated by the GOCS (Glasgow Outcome Coma Scale), with a score 
of 5 for favorable outcome, 4 for moderate disability, 3 for severe disability, 2 for persistent  
vegetative state, and 1 for death [16]. 
drenal status and wider pituitary function was re-evaluated during the recovery phase, 
defined as three months after TBI in surviving patients. ITT was performed in the absence of 
contraindications, e.g. seizures, as recommended by the consensus guidelines on screening for 
hypopituitarism after brain injury [17]. Insulin was given in the dosage of 0.1 units/kg and 
requiring a glucose nadir of <2.2 mmol/L to represent adequate hypoglycaemia.  
Sampling was carried out at baseline, 15, 30, 45, 60, 90 and 120 minutes and AI was defined 
as peak cortisol <500 nmol/l.  Growth hormone deficiency during ITT was defined as a peak 
value of < 5 µg/L (15mIU/L), gonadotrophin deficiency as serum testosterone or estradiol 
levels below the reference range (testosterone <8 nmol/l in males and estradiol <60 pmol/l in 
non-menopausal women with normal/low gonadotrophins, hypoprolactinaemia as prolactin 
<73 mIU/L and hyperprolactinaemia as prolactin > 474 mIU/L in men and > 502mIU/L in 
women,  thyrotropin deficiency as free thyroxine < 6.35 pg/L (<8.4 pmol/L) with normal or 
low TSH. 
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Statistical analysis was performed using Student t test of CHI tests for between group 
comparisons. Comparison of means was with ANOVA or Krushall-Wallis test, and Pearson 
coefficient was used for analyzing quantitative variables. The measure of variance used was 
the standard  deviation.  Data analysis was with SPSS version 21. Receiver operator curve 
(ROC) analysis was carried out to determine the value of acute phase cortisol in predicting 
cortisol insufficiency (peak stimulated cortisol < 500 nmol/L) during the recovery phase. 
The Scientific and Ethics Committees of the central hospital of Army and the Medical Faculty 
of Algiers approved this study. Consent was obtained from the families of patients for cortisol 
samples to be taken during the acute phase of TBI. Written consent was also obtained from 
patients (where appropriate) and families for repeat adrenal function testing during the 
recovery phase.  
Results 
 
Between November 2009 and December a total of 277 Algerian patients with moderate or 
severe TBI were seen and their details are shown in Table 1.There was a strong male 
predominance (93%) in the study population, age ranging from 18 to 65 years. RTA was the 
most frequent cause of brain injury, occurring in 48% of patients (M: 128, F: 4). Ninety-eight 
patients (35.5%) died (GOCS =1) after a median hospital admission of 10.4 ±11.6 days 
including 45 (45. 9%) deaths during the first week. However, half of the patients (n=140) had 
a good outcome with GOCS 5. 
 
Data relating to neurological status during acute phase of TBI: 
Of the 277 patients, 144 (48%) had moderate and 133(52%) severe TBI according to GCS, 
and 177 (63.8 %) were intubated for a mean period of 7.2 ±11 days. Mean duration of coma 
was 9.54±16.5 days. 95 (34. 3%) of the patients had multiple injuries while 116 (42%) had 
intracranial surgery. During the first week 85  (30.7%) of the patients had anemia with  Hb < 
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9g/dl  and 64 (29.1%) were hypotensive with systolic or diastolic blood pressure < 90/60 
mmg Hg on  admission to the intensive care unit. Concerning pupillary status, 169 patients 
(61%) had isocoric pupils with anisocoria in 61 (22%) and mydriasis in 47 (17%). CT 
imaging showed complex lesions in 224 patients associated with fractures, arachnoid 
hemorrhage and hematoma while 58 patients had isolated intra-parenchymal hematoma and 
53 (19.1%) had skull base fracture. 
Eight patients developed diabetes insipidus during the first week, all of whom died. During 
the post-traumatic acute phase 168 (60.6%) patients were sedated with Midazolam (n=155), 
Propofol (n=5), Penthotal (n=25), Fentanyl or Sufentanyl (n=162) and Phenobarbital (n=7).  
 
Cortisol data during the acute phase of TBI (See Figure 1):  
 
A single cortisol sample was taken during the acute phase of TBI from all 277 patients with a 
median (range) time at sampling of 3 (1-7) Analysis using one-way ANOVA showed no 
significant differences in the cortisol levels according to the day of sampling (p = 0.32). Mean 
morning cortisol was 573.1 ± 376 nmol/l and there was no difference between patients with 
severe and moderate TBI: 541.9 ± 308.1 versus 606.9 ±436.8 nmol/l (p=0.15). Serum cortisol 
was ≤ 83 nmol/l in 8 (2.9 %) patients, ≤ 276 nmol/l in 56 (20.2%) and ≤ 414 nmol/l in 98 
(35.4%)  
Seven patients were given hydrocortisone replacement at the discretion of their attending 
physicians ; four with cortisol levels <83 nmol/l and three with cortisol <276 nmol/l in whom 
hemodynamic instability was present. No patient with cortisol >414 nmol/l received 
glucocorticoids. 
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 Factors associated with low cortisol cut-offs during acute phase of TBI (see table 2) 
Table 2 shows the bivariate analysis comparing the patients with and without post traumatic 
AI according to the three chosen cut-off levels of cortisol. No association could be found 
between the three cortisol cut-offs and severity of TBI according to GCS or pupillary status.  
However, the presence of intra-parenchymal haematoma was predictive of AI for all three 
cortisol cut-offs. Diastolic blood pressure < 60 mmHg was associated with AI for the 83 and 
276 but not the 414 nmol/l cut-offs There was no significant association between anemia and 
AI but acute insipidus diabetes was associated with AI at the 414 nmol/l cut-off level.   
The prescription of Pentothal and Propofol in sedated patients was associated with cortisol 
level < 83 nmol/l, indicating a strong correlation (p: 0. 00004-p: 0.022). These findings were 
not found for the other agents.   
Multiple extracranial injuries and cranial surgery were not associated with posttraumatic AI. 
Mortality was not significantly associated with AI for the three cortisol cut-offs. However, the 
highest mortality was seen in patients with acute cortisol <276nmol/l (44.6% with OR for 
death of 1.64, 95% CI 0.92-3.0, p=0.12)  
 
Adrenal axis function during the recovery phase of TBI (see Figure2): 
Figure 2 shows the outcome of adrenal testing during the recovery phase, grouped according 
to cortisol cut-off values during the acute phase of TBI. Of 179 patients who survived TBI 
repeat testing was successfully carried out three months later in 133 (74%). AI was found in 
all 3 surviving patients with initial cortisol <83 nmol/l and in 12/24 and 4/16 patients with 
acute phase cortisols of 84-276 and 277-414 nmol/l. AI was also found in 20/66 (30%) 
patients with initial cortisol >414 nmol/l. 
ROC curve analysis showed no meaningful correlation between acute cortisol and the 
response to ITT three months later indicating that no acute cortisol cut-off was of predictive 
value. 
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Pituitary function during recovery phase 
The overall prevalence of post traumatic hypopituitarism three months after injury was 44% 
with corticotrophin deficiency in 39 (29, 3%) patients; growth hormone deficiency in 24 
(18%); gonadotrophin deficiency in 9 (6.8%); hypoprolactinemia in 9 (6.8%);  
hyperprolactinaemia in 5 (3.8%) and thyrotropin deficiency in 2 (1.5%). 
 
Discussion 
TBI is an important public health problem and remains the leading cause of handicap and 
disability in young adults [2]. Victims are usually young adult males with RTA and falls 
being the most frequent causes [1, 2]. The prevalence of TBI in Algeria is unknown, but the 
frequency of RTA is ranked among the top five countries in the world, with 3000 deaths and 
25,700 injured during 2016 [18] .  
The outcome in severe TBI is generally poor, and the presence of neuroendocrine 
complications may further worsen the prognosis [12, 13]. Early diagnosis of AI in TBI is 
therefore important since timely recognition and treatment may improve the prognosis. While 
AI in the setting of TBI is well-recognized [14], the cut-off values for cortisol defining its 
presence remains problematic.  
Serum cortisol is typically increased during the acute phase of TBI. Levels of > 550 nmol/l 
(20µg/dl) are usual and have been linked to increased mortality [19]. Increased secretion due 
to activation of the corticotrophin axis, mediated by hypothalamic CRF secretion in response 
to stress [8, 9], is one explanation for this finding. Another proposed mechanism is cortisol 
resistance in target tissues, caused by the increased cytokine secretion which occurs in 
response to brain injury [8, 9]. The use of medication in the acute phase of TBI may also 
modify cortisol metabolism both by inhibiting steroidogenesis and by acting as enzymatic 
inducers [8, 13].  
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Cortisol levels of <83-138 nmol/l during the acute phase of TBI clearly demonstrate an 
impaired response of the adrenal axis to stress and indicate AI. However, values >138 nmol/l 
cannot exclude the possibility of AI especially in critical illness; indeed the appropriate cut-
off level defining AI is still not established [8, 13, 14].  
Table 3 shows data from fifteen studies of cortisol levels in acute TBI. The American College 
of Critical Care Medicine, after a literature review, proposed a cortisol cut-off 276 nmol/l  as  
level defining adrenal deficiency in critical illness [11]. Cohan et al advised using a 414 
nmol/l (15µd/dl) cut-off to confirm AI in acute TBI after a study in which 80 victims were 
compared with a control group [13]. Hannon et al recommended the same cut-off level for 
defining post traumatic AI [14]. 
 Mean cortisol in our sample of patients was 573.1 ± 376.2   nmol/l and is in keeping with 
other studies [13, 20, 21].  Lower values were reported by authors who evaluated cortisol 
levels in TBI victims without prior exclusion of patients receiving glucocorticoids [22, 23]. 
In the present study, the prevalence for the lowest cortisol cut-off level of 83 nmol/l was 
2.9%, almost identical with the prevalence reported in other studies [19, 24, 25]. 
For the middle cortisol cut-off of 276 nmol/l, the prevalence of AI was 20.2% in our study, 
contrasting with the higher figures of 54% and 70% prevalence values reported by Olivecrona 
et al on the first and fourth post TBI days [26] and the lower prevalence of 9.8% reported by 
Tanriverdi et al [21]. These discrepancies are at least partly explained by variation in the 
severity of TBI in the different studies. Thus, Olivecrona et al described 48 patients with 
severe TBI - GCS<8 and intracranial pressure >10mmHg [26]; while Tanriverdi et al, using a 
200 nmol/l cortisol cut-off, studied 52 patients with minimal, moderate and severe TBI during 
the first 24 hours [21].  
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For the top cut-off level of 414 nmol/l, the prevalence frequency of AI in our study was 35.4 
%, compared with 53% in the study of Cohan et al who measured cortisol twice daily for the 
first nine days in 80 victims of moderate to severe TBI [13]. 
Hannon et al studied 100 TBI victims aged 18-75 years with GCS<14 and compared them 
with 50 controls, measuring cortisol at admission and during the ten consecutive days.  
Cortisol levels in controls was >500 nmol/l whereas 78% of injured patients had values <300 
nmol/l on the first day which was still low in 63% patients on the 3
rd
 day. Cortisol levels 
increased thereafter at the 10 day after injury in 41 of patients (61. 5%)  [27].   
As shown in table 3, some authors have evaluated the corticotrophin axis using dynamic tests 
and shown a degree of AI in 4 to 24% of cases, depending on the time of testing, the 
populations studied and the severity of TBI.  
In our study, re-evaluation of adrenal status was carried out in nearly three quarters of 
surviving patients. AI was found in all three survivors with the lowest cortisol cut-off of <83 
nmol/l, half of the 24 survivors with acute phase cortisol values of 84-276 nmol/l and in only 
4 of the 16 patients with initial cortisol 277-414 nmol/l. However, 30% of the patients with 
initial cortisol > 414 nmol/l fulfilled the criteria for AI on retesting showing the poor 
predictive value of acute phase cortisol in response to ITT three months later.   
These data are consistent with acute AI being transient in some cases due to factors such as 
medication and hemodynamic disability while true corticotrophin deficiency from pituitary 
damage may have resolved three months later with resolution of contusion to pituitary tissue. 
By contrast, corticotrophin deficiency may develop in some patients during the recovery 
phase of TBI. This pattern of evolving AI has been reported by Tanriverdi et al who reported 
that pituitary hormone deficiencies recovered in 30 (57.7%) patients after one year, while new 
pituitary hormone deficiencies were present in 27 (51.9%) patients after one year [21]. 
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Schneider et al studied 1242 victims of TBI and showed that acute adrenal deficiency could 
resolve but could also develop five months after the event [33]. 
The factors linked with AI in the context of brain injury include GCS, anemia, hypotension, 
pupillary status, cranial lesion, skull base fracture, cranial surgery and intra-cerebral pressure.  
Cohan et al have reported a correlation between AI and GCS<13 [13], a finding supported by 
the present study and three other studies [18, 22, 26]. Ischaemic factors such as anemia, 
hypoxia and hypotension are known to cause pituitary damage in Sheehan’s syndrome [7, 8]. 
In this study, we found that diastolic hypotension but not anemia was predictive of acute 
posttraumatic AI. Similarly, Cohan et al found a positive correlation between AI and mean 
blood pressure of <60mmHg but not for hypoxia and anemia [13].  
We found a relationship between the presence of intra-parenchymal hematoma and 
posttraumatic acute AI but this was not found by Agha or Olivecrona  [24,26].  We also found 
a relationship between skull base fracture and AI for cortisol cut-offs of 276 and 83 nmol/l. 
This finding is consistent with fractures through the skull base and the sella turcica directly 
injuring the pituitary gland and inducing corticotrophin deficiency.  
Finally, we found that among the medications used in sedation during the acute phase of TBI, 
Pentothal and Propofol were strong predictors of acute post-traumatic AI. This is consistent 
with data from Cohan et al who found an association with  
Pentobarbital and Propofol and posttraumatic AI [13]. High dose use of Propofol and 
Pentobarbital induce an inhibition of steroid genesis while Phenobarbital is an enzymatic 
inducer. In situations where these agents interfere with the corticotrophin axis, the challenge 
is to distinguish between medication-induced or organic posttraumatic AI since this will affect 
the need and the duration for steroid treatment. For this reason, Cohan et al. recommend 
monitoring cortisol levels in intubated patients with traumatic head injury, particularly those 
receiving high dose of Pentobarbital or Propofol [13]. 
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Polytrauma was studied as a risk factor for AI in our series given its potential effect on 
haemodynamic status which could in turn result in pituitary necrosis. However, neither this 
factor nor cranial surgery could not be shown to affect the prevalence of posttraumatic AI  
The frequency of posttraumatic diabetes insipidus was 2.8% in our study, consistent with the 
2.9% prevalence reported by Boughey et al [344]. This contrasts markedly to the very high 
figure of 26% in 50 TBI victims described by Agha et al and may be explained by the high 
proportion of patients with severe injury (64%) in that study [24]. Diabetes insipidus in TBI is 
usually transient, lasting between hours and several days although some studies have shown 
permanent deficiency. In fact. Agha reported the persistence of diabetes insipidus in 8 of 23 
victims of TBI 6 to 36 months after injury with an incidence of 6.9% while Aimaretti showed 
a similar incidence three months after TBI [24, 35]. 
In the present study, the presence of DI was correlated with acute AI for cortisol levels less 
than of 414 nmol/l, the putative mechanism being ischaemic or haemorrhagic insult to the 
posterior and anterior pituitary causing both DI and corticotrophin deficiency. All the patients 
with DI in our study had severe brain injury with GCS<8 and all died.  
An association between acute posttraumatic AI and mortality could not be shown in our study, 
in keeping with the work of Della Corte et al and Olivecrona et al. [26, 28] and in contrast to 
Hannon et al [14].  Nor could we confirm the work of Kakatti et al who showed a correlation 
between elevated cortisol levels of > 23µg /dl (634 nmol/l) and increased mortality [19]. 
Nevertheless, the higher mortality seen in those of our patients with acute cortisol <276 
nmol/L has influenced our recommendations for clinical care as shown below.  
Figure 3 shows a proposed algorithm for the acute and subsequent adrenal evaluation of 
patients with moderate and severe TBI, and which takes account of the findings of this and 
other studies. 
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In patients with AI risk factors such as diastolic hypotension, intra-parenchymal hematoma, 
diabetes insipidus, skull base fracture, and the prescription of sedatives such as Penthotal and 
Propofol we recommend immediate cortisol sampling. This should be followed by 
hydrocortisone cover in those patients with cortisol <276 nmol/L given that mortality was 
higher in such patients. We also advise cortisol cover in patients with cortisol <414 nmol/L in 
whom AI risk factors persist given the Cohan recommendations [13-14] and recognizing that 
cortisol values of <500 nmol/L in stressed patients with TBI are relatively low [19]. The 
rationale for choosing the <414 nmol /l in patients with no AI risk factors, a serum cortisol 
should be taken during the first week. Given the poor correlation between acute and 
subsequent AI, and the significant incidence of hypopituitarism shown in this study 3 months 
after TBI we recommend pituitary re-evaluation in all patients with moderate and severe TBI 
during the recovery period, irrespective of adrenal status during the acute phase.  
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Table 1. Characteristics of 277 patients during the acute phase of traumatic brain injury seen in two 
Algerian hospitals between November 2009 and December 2013.   Data are shown as mean ± standard 
deviation. 
1
Abbreviations: M = male, F = female, GCS = Glasgow coma scale, GOCS = Glasgow 
outcome coma scale, TBI = Traumatic brain injury, RTA =road traffic accident, Hy = Hypnovel, Pt = 
Pentothal, Ft=Fentanyl/Sufentanyl, Pr =Propofol, Gr = Gardenal. 
 
 
Studied Parameters  Results 
Sex M :257       F:20 
Age (years) 31.85 ±11.1 
Severity of TBI (GCS)
1
 
<8 
8-13 
 
144 (52%) 
133 (48%) 
Causes of TBI 
1
  
RTA 
Fall 
Explosion 
Other 
 
48% 
23.8% 
6.5% 
21.5% 
Anemia 85   (30. 7%) 
Sedation 168 (60.64%) 
Drugs used for sedation Hy
1
      Pt
1
        Ft 
1
       Pr
1
        
Gr
1
 
155      25        162     5         7 
Diastolic hypotension 46(16.6%) 
Systolic hypotension 18(12.5%) 
 
Pupillary status 
Isocoria-Anisocoria-Mydriasis 
  
169    -      61      -     47 
Mean intubation duration 7.2 ±11 days 
Mean coma duration 9.54±16. 52 days 
Diabetes insipidus 8 (2. 8%) 
Intraparenchymal hematoma 58 (20.93%) 
Skull base fracture 53 (19. 13%) 
Glasgow outcome coma scale 
(GOCS)
 1
 
 
1: 98  
2-3-4 :39   
5: 140   
 
 
 
 
 
 
 
                                                          
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2: Bivariate analysis of factors predicting Adrenal insufficiency (AI) using three chosen cortisol cut-offs: 83, 276 and 414 nmol/L. Significance for differences was set 
at p values <0.05. Glasgow outcome coma score (GOCS) of 1 equates to mortality, and GOCS2-3-4-5 refers to surviving patients 
                                        Cortisol levels Cortisol level <83 nmol/l     P Cortisol level< 276 nmol/l     p Cortisol level< 414 nmol/l    p 
Studied parameters AI                             No AI  AI                                   No AI  AI                                  No AI  
GOCS 8-13 
           <8 
2                              142 
6                              127 
0.12 28                                 116 
28                                 105 
0.73 54                                 90 
44                                 89 
0.4 
Presence of anemia 
Absence of anemia 
5                              82 
3                              185 
0.89 15                                 70 
41                                 149 
0.55 25                                 60 
72                                118 
0.22 
Presence of intraparenchymal hematoma 
Absence of intraparenchymal hematoma 
4                              54 
4                              215 
0.04 17                                 41 
39                                 180 
0 .05 27                                 31 
71                                148 
0.04 
Presence of SBF 
Absence of SBF 
4                              49 
3                              217 
0.02 16                                  37 
37                                 183 
0.032 27                                  33 
71                                 154 
0.61 
Pupillary statue            Anisocoria 
                                        Midriasis 
                                        Isocoria 
5                              164 
1                              60 
2                              45 
0.72 28                                 141 
15                                 46 
13                                 34 
0.15 54                                115 
23                                 38 
21                                 26 
0.24 
Cranial surgery 
No cranial surgery                                           
5                              111 
3                              158 
0.4 22                                 94 
34                                 127 
0.77 39                                 77 
59                                102 
0.69 
Polytraumatism 
No polytraumatism                                        
4                               91 
4                              177 
0.57 21                                 74 
34                                 147 
0.61 35                                  60 
62                                  119 
0.63 
Insipidus diabetes    
No insipidus diabetes                                                     
2                               6 
6                               262 
0.0001 4                                    4 
52                                 216 
0.034 6                                    2 
92                                   176 
0.018 
Mean systolic pressure    111.250±9.59     
114.197±24.2 
0.34 113.69±18.75       114.21±25.27 0.78 116±21 .01                112±25 .55 0.33 
Mean diastolic pressure 60±10.69           66±16.28 0.012 63.05±13,16            0.04 65 .31±14.42            66 .31±17.07 0.42 
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66.58±16,79 
Penthotal  prescription                               
No Penthotal prescriptions                                                  
4                               21 
4              246 
0.00004 7                                    18 
48                                  201 
0.51 10                                  15 
87                                  162 
0.60 
Hypnovel  prescription                                                                                
No Hypnovel prescription 
2 153
6                               114 
0.07 29                                 126 
26                                  94 
0.51 52                                  103 
45                                  75 
0.46 
Fentanyl    prescription                                                                                
No Fentanyl prescription     
4 158
4                              108 
0.59 30                                 132 
25                                  87 
0.44 53                                  109 
44                                  68 
0.4 
Propofol   prescription                                                                             
No Propofol prescription 
1 4
7                               262 
0.022 1                                    4 
54                                  215 
0.9 2                                    3 
95                                 174 
0.61 
Gardenal prescription 
No Gardenal prescription 
0                               7 
8                              259 
0.64 2                                    5 
53                                  214 
0.57 4                                    3 
93                                  174 
0.22 
GOCS :GOCS1 (mortality) 
            GOCS 2-3-4-5 
5                               93 
3                              176 
 
0.10 
25                                  73 
31                                  148 
 
0.1 
 
35                                 63 
63                                  116 
 
0.64 
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Table 3. Frequencies of acute AI in the setting of TBI reported in the literature. Mean cortisol values are expressed in nmol/l ±SDS. The method of evaluation of corticotrophin function, cut 
offs used in every study and time of testing are given.  
                                                          
2
 Abbreviations: D = day, NA = not available  
Author & Year 
             [reference] 
Number of  patients 
Mean age   
Day of sampling Parameter measured 
Cortisol cut-off used (nmol/l) 
Mean  cortisol (nmol/l) % AI according to cut-off  
Hackl   1991  [24 ] 21 
30.5 years 
Acute phase Cortisol 126.5 NA
3
 
Della Corte 1998 [28] 22 D1- D7-D15
2
 Cortisol    D1 :225±40.9 
  D7 :189.73±18.6  
D15:20.4±6.8 
 
NA 
Cernak 1999 [29] 31 D7 Cortisol <200nmol/l 3 318.60 ± 10.056 
 
100% if GCS<7  
Agha   2004 [24] 50 
37±14 years 
D7-D20 Cortisol + Glucagon test Cortisol<450nmol/l 496±218 
 
16%  
Cohan 2005 [13] 80 
29 years 
D1-D9 Cortisol <414nmol/l 588.6-553.5 53%  
Tanriverdi 2006 [21] 52 
40.7-34.7-36.6 years 
24h Cortisol <200nmol/l 580.5 ± 496.8 9.8% 
Dimopoulou   2004 [32] 37 
45 years 
Mean of 16 days Synacthen 1µg<500nmol/l 419 
 
13% 
Klose 2007[20] 46 
38 years 
D1-D12 Synacthen 250µg Cortisol<500nmol/l 491 (98–1275) 
 
4% 
Krahulik 2010 [23] 186 
16-65 years 
Acute phase Cortisol- ACTH NA 10% 
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Schneider   2011 [34] 1242 
45.1 years 
<5 months post 
TC 
Cortisol + Synathen 250 µg NA 3% (cortisol) 
15% (synacthen 250µg) 
Olivecrona   2013[26] 48 
35.7±2.2 years 
D1-D4 Cortisol <276nmol/l D1:303±30 
D4 :494±168 
54% 
70% 
Hannon 2013[14] 100 
33 years 
D1-D10 Cortisol <300nmol/l 300-550 78% 
Kakati  2013[19] 30 
38 ±  19.1 years 
D1 Cortisol <138nmol/l NA 3.3% 
Prasanna  2015[25] 100 D1 Cortisol<138nmol/l NA 2% 
Dalwadi 2017[30] 49 D1 Cortisol <200nmol/l NA 12.24% 
Present study 
2015 
277 
32 years 
D1-D7 Cortisol <83nmol/l-276nmol/l-414nmol/l 573.07 ± 376 2.8%.20.2%.35 .3% 
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Figure 1: distribution of 277 samples of cortisol during the acute phase of TBI. 
Each point corresponds to a single cortisol sample from each patient between days 1 and 7. 
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Figure 2: Corticotropin evaluation in the recovery phase of traumatic brain injury group using the 
insulin tolerance test. Patients are grouped according to serum cortisol level during the acute phase of 
brain injury. Adrenal insufficiency (AI) during the recovery phase was defined as peak cortisol <500 
nmol/L.  
 
Total patients with TBI n=277 
Basal cortisol measured days 1-7 n=277 
Cortisol<83 nmol/l   
    n=8 
Cortisol 84-276 nmol/l  
     n=48 
Cortisol 277-414 nmol/l 
 n=42 
Cortisol >414 nmol/l  
n= 179  
Died in acute phase 
 n= 5 
Died in acute phase  
 n= 20 
Died in acute phase   
n= 10 
Died in acute phase 
n= 63 
Retested in  
recovery phase 
AI: n =3 
No AI: n =0  
Retested in 
 recovery phase 
AI: n =12 
No AI: n =12  
Retested in 
 recovery phase 
AI: n =4 
No AI: n=16 
Retested in  
recovery phase 
AI: n =20 
No AI: n =66  
Not retested in 
 recovery phase 
n= 0 
Not retested in 
 recovery phase 
n= 4 
Not retested in 
recovery phase 
n= 12 
Not retested in 
 recovery phase 
n= 30 
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Figure 3: Proposed algorithm for the management of acute adrenal insufficiency (AI) 
following traumatic brain injury (TBI).  
IV Hydrocortisone: 100mg every 6 hours during 24-48 h 
Then reduce the dose to half every 24 to 48 hours 
Final dose 15-20 mg of Hydrocortisone daily 
Either Cortisol <276 nmol/L, or  
Cortisol <414 nmol/L in presence of AI signs 
Moderate to severe TBI (GCS<13)  
 
 
 
 
 
Cortisol<500 nmol/L 
Maintain or commence Hydrocortisone treatment 
 
Cortisol>500 nmol/l 
Discontinuation of treatment (where applicable) 
 
Draw sample for serum cortisol immediately 
Cortisol ≥ 414 nmol/L 
Monitor progress, repeating serum cortisol 
measurement if clinically indicated 
No risk factors of AI 
 
 
 
 
Risk factors for AI  
Skull base fracture 
Diabetes insipidus 
Hemodynamic disability 
Pentothal, Propofol, Penthobarbital 
 
 
 
 
 
Measure serum cortisol between 1-7 days  
3 months after TBI (all patients with moderate and severe TBI irrespective of 
acute status) 
Synacthen test or ITT 
 
